Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

Recruiting Observational Study
Hematologic Malignancy
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
20 (estimated)
Sponsor
Northside Hospital, Inc. · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Availability of 3/6 - 5/6 matched related donor with a negative HLA-cross match in the host vs. graft direction willing to donate peripheral blood stem cells * KPS \>/= 70% * Hematologic malignancy requiring allogeneic transplantation, with a predicted high risk of relapse fol…
Contacts

Stacey Brown

404-480-7965

stacey.brown@northside.com

CONTACT

Caitlin Guzowski

404-851-8523

caitlin.guzowski@northside.com

CONTACT